Apellis Pharmaceuticals, Inc. (APLS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -60.97M | -14.18M | 108.47M | 4.45M | -53.41M | 19.36M | 34.1M | -8.34M | -132.98M | -97.88M | -169.09M | -150.16M |
| Operating CF Margin % | -31.75% | -7.09% | 23.65% | 2.49% | -32.02% | 9.11% | 17.32% | -4.18% | -77.17% | -66.86% | -153.16% | -158.11% |
| Operating CF Growth % | -14.15% | -173.22% | 218.13% | 153.3% | 59.84% | 119.78% | 120.17% | 94.45% | 25.13% | 30.46% | -9.5% | -40.3% |
| Net Income | 18.66M | -81.34M | 215.72M | -42.15M | -92.22M | -36.35M | -57.45M | -37.66M | -66.42M | -88.58M | -140.24M | -122.04M |
| Depreciation & Amortization | 291K | -1.23M | 339K | 446K | 446K | 447K | 457K | 449K | 444K | 490K | 537K | 410K |
| Stock-Based Compensation | 0 | -82.76M | 28.19M | 27.2M | 27.37M | 26.31M | 27.48M | 29.99M | 30.35M | 26.22M | 21.63M | 29.28M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 25.83M | 128.6M | 636K | 614K | 591K | 587K | 822K | 5.06M | 6.14M | 6.55M | -3.06M | 6.52M |
| Working Capital Changes | -105.75M | 22.55M | -136.41M | 18.34M | 10.4M | 28.36M | 62.79M | -6.18M | -103.5M | -42.56M | -47.95M | -64.33M |
| Change in Receivables | -74.07M | -20.67M | -131.4M | 21.12M | 29.68M | 14.09M | 25.42M | -36.58M | -61.41M | -37.17M | -58.36M | -79.41M |
| Change in Inventory | 18.81M | -8.66M | 5.4M | -26.01M | 14M | 10.02M | 8.65M | -14.51M | -14.92M | -47.82M | 4.67M | -17.65M |
| Change in Payables | -7.74M | 18.2M | -15.64M | -1.04M | 16.71M | 1.49M | -1.16M | 11.49M | -10.73M | 19.62M | 0 | -4M |
| Cash from Investing | 0 | -108K | -148K | -49K | -8K | -20K | 0 | -90K | -293K | 4K | -47K | -372K |
| Capital Expenditures | 0 | 205K | -148K | -49K | -8K | -20K | 0 | -90K | -293K | -95K | -47K | -372K |
| CapEx % of Revenue | - | 0.1% | 0.03% | 0.03% | 0% | 0.01% | - | 0.05% | 0.17% | 0.06% | 0.04% | 0.39% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -313K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 64K | 1.26M | 793K | 6.56M | 274K | -4M | 2.54M | 42.49M | 108.21M | -3.91M | 5.75M | 1.56M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -5.63M | 0 | 37.33M | 98.76M | 24.5M | 0 | -24.5M |
| Equity Issued (Net) | 86K | 1.26M | 797K | 6.56M | 281K | 1.64M | 2.56M | 5.16M | 98.76M | 27.09M | -11K | 26.09M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11K | 0 |
| Other Financing | -22K | 0 | -4K | 0 | -7K | -15K | -14K | 0 | -89.31M | -55.5M | 5.76M | -28K |
| Net Change in Cash | -61.03M | -12.84M | 109.14M | 11.64M | -52.78M | 14.38M | 36.81M | 34.4M | -25.27M | -101.2M | -163.84M | -149.01M |
| Free Cash Flow | -60.97M | -13.97M | 108.32M | 4.4M | -53.42M | 19.34M | 34.1M | -8.43M | -133.28M | -97.97M | -169.13M | -150.53M |
| FCF Margin % | -31.75% | -6.99% | 23.62% | 2.46% | -32.03% | 9.1% | 17.32% | -4.22% | -77.34% | -66.93% | -153.2% | -158.5% |
| FCF Growth % | -14.13% | -172.24% | 217.69% | 152.15% | 59.92% | 119.74% | 120.16% | 94.4% | 25.07% | 30.81% | -9.39% | -40.14% |
| FCF per Share | -0.48 | -0.11 | 0.86 | 0.03 | -0.43 | 0.16 | 0.28 | -0.07 | -1.08 | -0.81 | -1.41 | -1.26 |
| FCF Conversion (FCF/Net Income) | -3.27x | 0.24x | 0.50x | -0.11x | 0.58x | -0.53x | -0.59x | 0.22x | 2.00x | 1.10x | 1.21x | 1.23x |
| Interest Paid | 0 | 0 | 0 | 0 | 11.09M | 0 | 12.5M | 0 | 0 | 0 | 1.64M | 0 |
| Taxes Paid | 0 | 0 | 0 | 666K | 141K | 0 | 600K | 0 | 0 | 0 | 0 | 0 |